INTRODUCTION urton et al; 2008
stated that The percentage of Tregs was higher in NR than in SVR patients before and at 24 weeks post-treatment and in early NR than in SVR patients at baseline, thereby suggesting a possible role of Tregs in virological response to combined antiviral treatment. To our knowledge, only one longitudinal study has examined the effect of combined antiviral treatment in Tregs frequency, finding no differences on the percentage of Tregs before, during or after treatment or between NR and SVR patients.
(1( Study on untreated population Ebinuma et al; 2008 stated that another lymphocyte subpopulation studied in patients with HCV infection is the CD4+T-reg cells have an important role in either disease progression or control. The percentage of Tregs in peripheral blood in patients with chronic HCV infection is either similar or increased compared with recovered HCV patient. (2) Akiyama et al; 2010 stated that Treg levels (CD4+CD25+Foxp3+) have already been evaluated during antiviral HCV therapy, and it has been suggested that they could predict the result of combination therapy. (3) Given the high potency of DAAs, it is unclear whether immune response plays a significant role in viral eradication. However, in a recent study of patients treated with SOF and ribavirin, Meissner et al; 2007 demonstrated that the resetting of intrahepatic type I interferon response was associated with SVR, suggesting a role for healthy liver in aiding HCV clearance, even in the setting of interferon-free therapy. (4) Our study aimed to assess the influence of baseline T-regulatory cells on the response to treatment with DAA and liver disease severity. Written informed consent was taken from the patients' relatives to participate in the study. Approval for performing the study was obtained from The Institutional Review Board (IRB) approval, also according to the declaration of Helsinki. Study design: prospective cohort study All subjects of the study were subjected to:
SUBJECTS AND METHODS
Full history and thorough clinical examination as well as drug prescriptions were done. General examination and local examination of different systems with gastrointestinal examination were done also.
Routine investigations were done according to the protocol of clinical pathology and laboratories of Zagazig University Hospital:
Complete blood count, Liver Kidney function tests, α-fetoprotein level, PT INR and RBS.
Radiological investigation: Pelviabdominal ultrasound, CT if suspicious HCC.
Quantitative real-time PCR: Before the start of the treatment to detect baseline HCV RNA viral load and we followed up the patients for 12 weeks then the PCR was repeated after the end of treatment for Assessment of response to DAA treatment (SVR).
Special investigations (flow cytometry analysis (
Reveal specific markers of T-reg cells including (CD4+, CD25+, and FoxP3+) through five ml of peripheral blood (PB) were drawn from the patients. Each blood sample inserted in 2 ml EDTA tube for immunophenotyping, Flow cytometry was performed on the same day of the arrival of the specimens.
Evaluation of flow cytometry results
Primary gating of cells was performed using FSC/SSC technique to detect lymphocytes, Then CD4 + cells are identified by flow cytometer and detected as T-helper lymphocytes, CD25 cells surface marker used to identify the T-reg cells (CD4+CD25+) in the upper right quadrant (UR area(. furthermore, expression of the most specific molecule for identification of Tregulatory cells is called forkhead protein-3 called as (Fox-P3) identified by gating in the position of CD4+/CD25+ve to identify the FOXp3+ve T-regs.
Statistical Analysis:
All data were analyzed using SPSS 20.0 for Windows (SPSS Inc., Chicago, Illinois, USA.)
Continuous variables were checked for normality by using the Kolmogorov Smirnov test. One-Way ANOVA was used to compare normally distributed variables in three groups. Post-hoc Fisher's Least Significant Difference test (LSD) tests were used according to the homogeneity of variances. Percent of categorical variables were compared using the Chi-square (χ2) test. Multivariate regression analysis was done to investigate independent predictor for both SVR and cirrhosis. Pearson product-moment correlation coefficient was used to assess the correlation between TE and study parameters if data is parametric while Spearman's rank correlation coefficient (Spearman's rho) was calculated to assess the correlations between MPV and various study parameters.
Receiver operating characteristic (ROC) curve analysis was used to identify optimal cut-off values of. < 0.05 was considered statistically significant (S), and p ≥ 0.05 was considered none statistically significant (NS). RESULTS Comparing SVR and NR groups , NR group shows higher (CTP, APRI, and FIB-4 ) and platelets , albumin bilirubin levels ,While no differences between both groups regarding age , gender , BMI , HCV RNA viral load, ALT ,AST or ribavirin use , flow-cytometry analysis shown that FOXp3+ve Tregs are significantly lower in the SVR group , +ve correlation between FOXp3+ve Tregs and markers of liver disease severity scores (CTP , APRI, FIB-4) , ALT, AST, α-Fetoprotein but -ve correlation with Platelets count while no correlation with either Age, BMI, baseline HCV RNA viral load or MELD score after that multivariate regression analysis resulted had shown FOXp3+ve Tregs as independent predictor for SVR in CHC patients with DAA therapy with cutoff value= 6.92% with sensitivity= 91% ,specifity= 98% ,+ve predictive value =98% and -ve predictive value = 36.4 % by ROC analysis ( Table 2 , 4, 5).
There is statistical significant difference between Non-Cirrhotic and both Cirrhotic child(A) , child (B) groups in liver functions like higher ALT, AST, α-Fetoprotein, and INR also higher (CTP , APRI and FIB-4 scores) but lower platelets count and albumin level while no significant difference regarding Age, gender, BMI, baseline HCV RNA viral load, by flow cytometry analysis we found that all Tregs subsets are significantly lower in Non-Cirrhotic compared to Cirrhotic CHC patients (Table 3) . Table 5 Binary logistic regression analysis of best predictor for sustained virological response. In this study revealed a SVR rate about (93.6%), the previous is similar to what reported by Webster DP et al; 2015 who informed that treatment with direct-acting antiviral (DAA) drugs, either alone or in combination with IFN-α, have achieved sustained virological response (SVR) in over 90% of treated patients. (7) Comparison both SVR and NR groups had revealed that NR groups were higher in child-pough , APRI , FIB-4 scores ,While no differences between both groups regarding age , gender , BMI , HCV RNA viral load, ALT ,AST or ribavirin addition and that concordant to study by Christoph Werner et al;2016 who considered sex, age, baseline viral load, and early virological kinetics were found not to be significant as predictors of SVR12 , thus costly "in-between" measurements of HCV viral load possibly are expendable. (8( Although there was an increased value of ALT & AST in NR compared to SVR group but this increase wasn't statistically significant, in converse to Billerbeck et al; 2007 who studied INFassociated SVR, reported that there was a significant increase in the value of ALT & AST in non-responder group compared to responder one. (9( Regarding AFP level as an important marker of hepatic inflammation, our results showed marked difference in its level between SVR and NR groups this goes with Hayashi et al; 2000 who stated that persistence of ALT elevation is a convenient marker for identifying an increased risk for HCC. In fact, the risk of HCC was significantly higher for SVR patients whose post-interferon treatment AFP or ALT levels were high (≥ 10 ng/mL and ≥ 40 U/L, respectively). (10) Our results had shown that treatment with (SOF, DCV ± R) for 12 week achieved SVR percentage about (93.6%) this goes Backus et al; 2015 who revealed that Patients with SOF, DCV ± R as combination partners (86%-93%) have been reported, containing hard-to-treat patients liver cirrhosis, portal hypertension and post-liver transplantation. (11( Our Regression analysis showed that platelets number and expression ratio of FOX-p3 is an independent factors for treatment failure others showed Data on HCV genotype, liver disease severity, and first and second line DAA regimens were prospectively collected in consecutive patients who reached the 12-week posttreatment and retreatment evaluations from January 2015 to December 2016 in 23 of The PITER network centers revealed that Among 3,830 patients with advanced fibrosis (F3) or cirrhosis, 139 (3.6%) failed to achieve SVR. So that study concluded that ,Genotype 3, bilirubin levels >1.5mg/dl, platelet count <120,000/mm3 and the sofosbuvir ± ribavirin regimen (SOF±RBV) were independent predictors of failure by logistic regression analysis. (12( Our results showed that NR group shows high T-reg levels and elevated serum alanine transferase as a marker of hepatic inflammation also T-regs may protect the host from liver destruction by suppressing immunoreactive T cells but in converse to our results, Manigold et al; 2007 stated that the frequency of n-T-reg in chronic hepatitis was not related to the grade of inflammation or the serum level of ALT. (13) Our study which compared pretreatment level of T-reg (BT) levels in both SVR Vs NR groups ,revealed that there is an elevated level of FOX-p3+ve T-regs (7.55±1.66%) in NR compared to SVR group (5.61±1.35%) then by ROC curve estimation that 6.92% cutoff level for can differentiate SVR and NR groups with sensitivity= 91% ,specifity= 100% this goes with INFbased study by Burton et al; 2008 who stated that The percentage of regulatory T cells was higher in non-responder patients, An increase in the percentage of T-regs during antiviral treatment was observed in both NR and SVR patients. The comparison of NR vs SVR at BT showed that NR had a significantly higher percentage of T-regs BT (NR: 3.42 ± 1.33% vs SVR: 2.49 ± 1.1%; P = 0.025). (1) Our results revealed that addition of RBV don't affect SVR out of 112 patients 32 didn't receive RBV had achieved SVR compared to 4 out of 8 patients who received RBV didn't achieve SVR (p-value=0.208) , Kumada et al; 2014 stated combination of sofosbuvir and daclatasvir DCV has been safe and effective, both, in previously treated and untreated HCV-patients with. In previously untreated HCV-infected patients, SVR-12 of 98 % was achieved with no significant impact of the duration of the treatment (12 wk vs 24 wk) or the addition of RBV. (14) Also results by Deterding et al; 2015 who stated that patients with liver cirrhosis show much lower response rates (87% with liver cirrhosis, 97% without; P = 0.005), and especially those with advanced portal hypertension (platelets <100/nL), or high MELD score (≥10) show significantly lower SVR12 rates than patients without (P < 0.0001, uni-and multivariate analysis). (15 ( Marked differences in the T-reg counts were noticed between Non_Cirrhotic group, Cirrhotic child (A) and child (B) also there is strong positive correlation between levels of FOX-p3+ve T-regs and ALT, AST and AFP levels so ,There is a proven correlation between the number of T-reg and occurrence of hepatic injury and cirrhosis this explained by Hartling et al; 2012 who informed that Persistent HCV-specific cytotoxic T-cell responses in the liver have been associated with the development of hepatic inflammation which may ultimately lead to liver cirrhosis. One of the potential mechanisms that might modulate hepatitis C virus (HCV)-specific immune responses is the inhibitory role of the regulatory T cells. (16) No correlation between baseline FOXP3+ve T-regs and baseline viral load (r = -0.014, P = 0.877) this in concordance Cabrera et al; 2004 who informed that trend towards a positive correlation between HCV-RNA level and CD81 expression levels on CD19+ B lymphocytes was observed at baseline also the percentage of T-reg level at baseline did not correlate with baseline HCV-RNA levels . (17( The previous in converse with Smyth MJ et al; 2006, Burton et al; 2008 whom had shown a positive correlation was detected between CD25 +ve CD4 T cell frequency and HCV RNA titer, whereas an inverse relation was found with liver inflammatory activity. They indicated that CD25+ CD4 T cells can respond directly to HCV antigens and suppress the HCV-specific immune response in a dose-dependent cell contact manner. (18,1( But according to Xu et al; 2006 T-reg considered to be enemy to our immunity, the proof may be the positive correlation between the HBV or HCV viral load and upregulation of CD4+CD25+ T-reg count. (19) In conclusion:
T-regulatory lymphocyte plays an important role in the natural course of HCV infection, response to treatment, and sequels of the infection with a strong correlation of the high levels of T-reg with the hepatic injury, cirrhosis in addition to the treatment failure.
Limitations of the study:
The high cost of the flow cytometry kits and no available studies on the post-treatment level of T-regs.
